International Registry and Biorepository for TMA(Thrombotic Microangiopathy)

An Observational Study of All Forms of Thrombotic Microangiopathy in Pediatric Patients

NCT00593229•Northwell Health

Summary

This registry will collect clinical data and store biosamples (seru, plasma, urine, and DNA) annually from pediatric patients with thrombotic mcroangiopathy

Detailed Description

Children age, 6 months - 18 years, are eligible if they have one of the following categories of thrombotic microangiopathy (TMA):(1) severe D+HUS; (2) non-familial atypical HUS; (3) familial atypical HUS; or (4) TTP Patients are seen intially and annually thereafter Biosamples are collected for storage annually.

Eligibility

Age

0 - 18 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Severe HUS, familial or non-familial atypical HUS, TTP

Exclusion Criteria

•None

Locations (1)

Schneider Chldren's Hospital

New Hyde Park, New York, United States

Key Dates

Start Date

January 1, 2007

Primary Completion Date

October 1, 2011

Last Updated

June 19, 2013

Enrollment

ACTUAL participants

Conditions

Thrombotic MicroangiopathyHemolytic Uremic SyndromeThrombotic Thrombocytopenic Purpura

Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy

NCT05805202

Atypical Hemolytic Uremic Syndrome

View study

RECRUITING

Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients

NCT07059026

Thrombotic Microangiopathy

View study

RECRUITINGPHASE4

Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 19, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

International Registry and Biorepository for TMA(Thrombotic Microangiopathy)

Inclusion Criteria

Exclusion Criteria

Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy

Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients

Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation

A Prospective Study on the Long-Term Vascular Burden in Thrombotic Thrombocytopenic Purpura Patients

Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome

National Registry of Rare Kidney Diseases